GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Panacea Biotec Ltd

Panacea Biotec: ITAT cancels ₹9.16 Crore tax demand for AY 2020-21

REGULATORY ▲ Positive Development MEDIUM RISK
📅 Filed on BSE: 30 Apr 2026, 11:11 AM IST  ·  BSE ID: 793526b7-b835-4a13-8d3b-bed9a2ee908a
View Original BSE Filing (PDF)
💡
In Simple Terms
A tax court ruled in Panacea Biotec's favor, canceling a ₹9.16 Crore income tax demand the government claimed for 2020-21.
🤖 AI Summary
  • ITAT Order dated April 29, 2026 cancels ₹9.16 Crore tax demand for Assessment Year 2020-21
  • Demand arose from Assessing Officer's ₹3.44 Crore disallowance under Section 14A read with Rule 8D
  • ITAT deleted disallowances and set aside CIT(A) Order dated August 14, 2025 upholding demand
  • Rectified Assessment Order dated October 10, 2023 effectively overturned; zero net tax liability remains
🔢 Key Numbers — exact figures from BSE filing, not rounded
Tax demand canceled
₹9.16 Crore
Disallowances deleted
₹3.44 Crore
Assessment Year
2020-21 (FY 2019-20)
ITAT Order date
April 29, 2026
🏢 How This Affects the Company
💰
Financial Impact
Cancellation of ₹9.16 Crore tax demand eliminates a liability previously recognized. This removes cash outflow pressure and improves balance sheet position for Assessment Year 2020-21.
⚠️
Risk Impact
Reduction in tax litigation exposure for AY 2020-21. However, company continues to face GST demands of ₹22.88 Crore (with interim High Court stay) and other pending tax matters.
👥 What This Means For Shareholders
✅
Action Required
No action required. This is a completed court order. Monitor High Court outcome on pending ₹22.88 Crore GST writ petition.
👤
Who Is Affected
All shareholders benefit from reduction in tax contingent liabilities and elimination of ₹9.16 Crore cash outflow requirement for AY 2020-21.
🔍
Management Signal
Management has successfully contested this income tax position at appellate tribunal level, demonstrating effective tax litigation capability on substantive grounds.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
High Court writ petition outcome on ₹22.88 Crore GST demand; interim stay status and merits hearing progress
Q4 FY26 financial results — verify impact of three tax reversals (₹65.10 Crore total) on tax provisions and cash
Future correspondence with Income Tax Department — monitor for any further notices or assessments for other assessment years
MEDIUM RISK AY 2020-21 resolved favorably. However, concurrent ₹22.88 Crore GST demand with only interim stay, tribunal awards on workmen dues, and multi-year tax scrutiny indicate elevated contingent liability exposure.
💡 Investor Takeaway
ITAT Order dated April 29, 2026 cancels ₹9.16 Crore tax demand for AY 2020-21 by deleting ₹3.44 Crore disallowances. This is the third material tax relief in April 2026. However, ₹22.88 Crore GST demand remains pending with only interim High Court stay.
⚖️ Strengths & Concerns

✅ Positives

  • ITAT order provides definitive closure on AY 2020-21 income tax dispute; no further appeal by tax authority disclosed
  • Third consecutive income tax relief in April 2026: ₹9.16 Cr + ₹10.23 Cr + ₹45.71 Cr demands resolved or reversed

⚠️ Concerns

  • Company remains exposed to ₹22.88 Crore GST demand with only interim High Court stay; merits decision pending
  • Multiple concurrent tax litigations across income tax and GST suggest broader tax compliance scrutiny ongoing
📅 Company Track Record
Panacea Biotec faced significant tax demands in FY26: April 7 filing reversed ₹10.23 Crore (AY 2016-17) and ₹45.71 Crore (AY 2015-16) via rectified assessments. April 30 filing cancels additional ₹9.16 Crore (AY 2020-21). Combined relief: ₹65.10 Crore. Separately, company received tribunal awards on 23 workmen claims and faces ₹22.88 Crore GST demand with High Court interim stay (filed March 31, 2026).

Based on publicly available historical data. For context only.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.